Skip to main content
. 2024 May 3;103:105137. doi: 10.1016/j.ebiom.2024.105137

Table 1.

Characteristics of the study cohort.

Control (n = 31) SCAD (n = 38) UA (n = 41) AMI (n = 22) CAD (n = 101)
Age, years 57.35 ± 8.20 62.53 ± 9.08 68.90 ± 9.78b 60.77 ± 10.09c 64.73 ± 10.13e
Female (%) 15 (48.39%) 13 (34.21%) 17 (41.46%) 5 (22.73%) 35 (34.65%)
BMI, kg/m2 24.88 ± 2.67 25.27 ± 3.06 24.66 ± 3.62 26.76 ± 3.08 25.35 ± 3.37
MAP, mmHg 93.03 ± 10.69 97.35 ± 12.20 96.14 ± 11.77 91.97 ± 13.20 95.69 ± 12.30
Smoke (%) 10 (32.25%) 20 (52.63%) 16 (39.02%) 8 (36.36%) 44 (43.56%)
Drinking (%) 5 (16.13%) 10 (26.32%) 10 (24.39%) 6 (27.27%) 26 (25.74%)
No. of SV
 NA NA 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
 1 NA 9 (26.4%) 6 (16.2%) 2 (12.5%) 17 (19.5)
 2 NA 5 (14.7%) 6 (16.2%) 2 (12.5%) 13 (15.0%)
 3 NA 16 (47.1%) 20 (54.1%) 6 (37.5%) 42 (48.3%)
 4 NA 4 (11.8%) 5 (13.5%) 6 (37.5%) 15 (17.2%)
Gensini score NA 43.00 (19.00, 81.25) 65.50 (41.00, 103.50)b 106.00 (84.00, 132.00)c 70.00 (33.00, 96.00)
Syntax score NA 15.50 (6.75, 23.75) 17.00 (11.00, 23.50) 29.75 (12.00, 32.75) 18.00 (10.00, 26.50)
Medication
Statins 4 (12.90%) 20 (52.63%)a 19 (46.34%) 7 (31.82%) 46 (45.54%)e
Antihypertensive drugs 7 (22.58%) 25 (65.79%)a 32 (78.05%) 11 (50.00%)d 70 (69.31%)e
Antidiabetic treatment 2 (6.45%) 20 (52.63%)a 11 (26.83%)b 8 (36.36%) 39 (38.61%)e
Laboratory data
TC, mmol/L 4.32 (3.94, 5.28) 3.82 (3.30, 4.60) 3.80 (3.28, 4.42) 4.01 (3.76, 4.40) 3.88 (3.39, 4.42)
HDL-C, mmol/L 1.19 ± 0.34 1.05 ± 0.33 1.00 ± 0.23 0.97 ± 0.25 1.01 ± 0.27f
LDL-C, mmol/L 2.90 (2.43, 3.60) 2.07 (1.70, 2.88) 2.39 (1.76, 2.67) 2.66 (2.18, 2.98) 2.39 (1.81, 2.83)f
TG, mmol/L 1.34 (1.05, 1.78) 1.18 (0.84, 1.89) 1.20 (0.96, 1.69) 1.49 (1.13, 1.70) 1.24 (0.96, 1.70)
Lp(a), mg/dL 13.35 (8.25, 28.00) 14.40 (7.60, 27.25) 21.00 (8.10, 39.60) 13.65 (9.525, 43.43) 15.70 (9.00, 36.10)
hs-CRP, mg/L 1.13 (0.63, 1.83) 0.76 (0.41, 1.84) 0.98 (0.53, 3.08) 5.42 (0.87, 22.48) 0.83 (0.49, 3.93)
BUN, mmol/L 2.80 ± 0.83 2.66 ± 0.60 2.84 ± 0.99 2.53 ± 0.78 2.70 ± 0.82
Cr., umol/L 71.50 (51.98, 79.63) 65.90 (55.70, 77.43) 68.00 (57.75, 80.05) 67.15 (59.25, 81.80) 66.70 (57.35, 79.75)
Uric acid, umol/L 348.5 ± 101.4 332.1 ± 83.95 341.4 ± 108.2 366.8 ± 142.8 343.4 ± 108.4
HCY, umol/L 12.50 (8.75, 14.75) 13.00 (11.00, 15.00) 14.00 (11.00, 17.00) 14.50 (13.25, 21.75) 14.00 (11.00, 16.00)
cTnI, ng/ml 0.00 (0.00, 0.00) 0.01 (0.00, 0.01) 0.00 (0.00, 0.01) 1.06 (0.23, 5.59)c 0.01 (0.00, 0.03)e
FBG, mmol/L 4.34 (3.81, 4.62) 4.77 (4.16, 6.42) 4.69 (3.91, 5.79) 6.37 (4.88, 7.87)d 4.89 (4.20, 6.55)f
HbA1c, % 5.70 (5.53, 5.80) 6.65 (5.90, 7.38)a 6.30 (5.73, 6.65) 6.10 (5.80, 8.00) 6.30 (5.80, 7.25)e
FT3, pg/mL 3.12 ± 0.56 3.30 ± 0.25 3.06 ± 0.40 2.76 ± 0.66 3.09 ± 0.45
FT4, ng/dL 1.24 (1.11, 1.32) 1.17 (1.03, 1.29) 1.20 (1.07, 1.32) 1.08 (1.03, 1.15) 1.16 (1.05, 1.30)
sTSH, uIU/mL 2.21 (1.40, 2.54) 2.14 (1.47, 3.59) 1.82 (1.25, 2.41) 2.70 (1.96, 5.98) 2.16 (1.38, 3.01)

Data following a normal distribution are presented as mean ± standard deviation; data not following a normal distribution are presented as median (IQR). Gender, Smoke, Drinking, No. of SV, Statins, Antihypertensive drugs and Antidiabetic treatment are shown as percentage (%). The analysis of normally distributed variables among the four groups was conducted using one-way ANOVA. Post hoc multiple comparisons of one-way ANOVA were performed using either the Games–Howell test or the Tukey–Kramer test. The Kruskal–Wallis H test was employed for data that did not follow a normal distribution. The χ 2 test was utilized to compare categorical variables. N/A indicates not applicable.

BMI, body mass index; MAP, mean arterial blood pressure. No. of SV, number of stenosed vessels; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; Lp(a), Lipoprotein(a); hs-CRP, hypersensitive C-reactive protein; BUN, blood urea nitrogen; Cr., creatinine; HCY, homocysteine; cTnI, cardiac troponin I; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; FT3, free triiodothyronine; FT4, free thyroxine; sTSH, serum thyroid-stimulating hormone.

a

P < 0.01 between CG and SCAD.

b

P < 0.05 between SCAD and UA.

c

P < 0.01 between UA and AMI.

d

P < 0.05 between UA and AMI.

e

P < 0.01 between CG and CAD.

f

P < 0.05 between CG and CAD.